Compare · NVO vs ZSTK
NVO vs ZSTK
Side-by-side comparison of Novo Nordisk A/S (NVO) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZSTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, NVO is down 34.2% and ZSTK is down 66.5% - NVO leads by 32.2 points.
- NVO has hit the wire 5 times in the past 4 weeks while ZSTK has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for ZSTK).
- Company
- Novo Nordisk A/S
- ZeroStack Corp.
- Price
- $41.18+6.93%
- $7.32+30.71%
- Market cap
- $220.35B
- -
- 1M return
- +13.32%
- -12.86%
- 1Y return
- -34.24%
- -66.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest ZSTK
- SEC Form 4 filed by Heinrich Michael
- Nasdaq-Listed ZeroStack Corp. Makes $107 Million Institutional Commitment To Increase Strategic Position in 0G Token Ecosystem
- ZeroStack Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- ZeroStack Announces $107 Million Cryptocurrency Financing, Elimination of Convertible Note and Plan to Redomicile to Texas
- ZeroStack Corp. Reports 3.2 Million 0G Tokens Earned in Staking Rewards at 22% APY
- ZeroStack Corp. Secures $6.5 Million Order from Major Pharmaceutical Company to Support Distribution in Germany
- SEC Form 10-K filed by ZeroStack Corp.
- ZeroStack Corp. Reports First One Million in 0G Token Staking Rewards at 21% APY